Intelligent Abuse-Deterrent Pharmaceutical Systems

Publication ID: 24-11857629_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Abuse-Deterrent Pharmaceutical Systems,” Published Technical Disclosure No. 24-11857629_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857629_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,629.

Summary of the Inventive Concept

The inventive concept integrates Acurx Pharmaceuticals' patented abuse-deterrent technology with cutting-edge technologies like AI, IoT, blockchain, and nanomaterials to create a new generation of smart pharmaceutical systems that optimize drug release, minimize abuse potential, and enhance patient safety.

Background and Problem Solved

The original patent addressed the need for abuse-deterrent pharmaceutical compositions. However, the growing opioid crisis and increasing concerns about prescription drug abuse necessitate more sophisticated solutions. The new inventive concept builds upon the original patent's foundation to create a more comprehensive and adaptive system that addresses the complex challenges of drug abuse and misuse.

Detailed Description of the Inventive Concept

The inventive concept combines Acurx Pharmaceuticals' pH-modifying technology with machine learning-based dosage monitoring, blockchain-based secure data storage, IoT-enabled ingestion tracking, and nanomaterial-based sensors. These integrated components enable real-time monitoring, adaptive drug delivery, and optimized release rates in response to patient behavior, dosage history, and environmental factors. The system's synergistic combination of technologies ensures a more effective and personalized approach to drug delivery, minimizing the potential for abuse and maximizing therapeutic efficacy.

Novelty and Inventive Step

The new claims introduce a paradigm shift in pharmaceutical systems by integrating distinct technologies to create a holistic, adaptive, and intelligent system that surpasses the original patent's limitations. The inventive concept's novelty lies in its ability to predict and respond to patient behavior, environmental factors, and dosage history in real-time, thereby providing a more effective and safer approach to drug delivery.

Alternative Embodiments and Variations

Alternative embodiments may include variations in the type of machine learning algorithm used, the specific IoT-enabled devices employed, or the nanomaterials utilized. Additionally, the inventive concept could be adapted for use with different pharmaceutical compositions, dosage forms, or routes of administration.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of pain management, addiction treatment, and personalized medicine. The system's ability to minimize abuse potential, optimize drug release, and enhance patient safety makes it an attractive solution for healthcare providers, pharmaceutical companies, and patients alike.

CPC Classifications

SectionClassGroup
A A61 A61K47/02
A A61 A61K9/2009
A A61 A61K9/2027
A A61 A61K9/2077
A A61 A61K31/5517
A A61 A61K47/32

Field of Art

Pharmaceutical formulations with abuse-deterrent technologies, focusing on controlled drug release mechanisms, pharmaceutical composition design, and drug delivery system optimization

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or chemical engineer with advanced degree, expertise in drug formulation, knowledge of controlled release technologies, understanding of polymer chemistry, and familiarity with abuse-deterrent pharmaceutical design strategies

Obviousness Rationale

A PHOSITA would recognize that integrating digital monitoring technologies with existing abuse-deterrent pharmaceutical compositions represents a predictable extension of known drug delivery strategies. The source patent's foundational work on pH-modulated drug release provides a clear technical framework for incorporating advanced monitoring and adaptive release technologies. The proposed variations represent logical combinations of known techniques in pharmaceutical engineering and digital health monitoring.

Obvious Combinations & Variations

Source Patent Element
Buffering ingredient for retarding pharmaceutical active ingredient release
PTD Variation
Machine learning-based dosage monitoring module predicting and adjusting release rate
Obviousness Reasoning
Predictable application of digital monitoring to existing controlled release mechanism, representing a routine technological enhancement
Source Patent Element
Acid soluble ingredient controlling drug release
PTD Variation
IoT-enabled ingestion tracking device monitoring and reporting ingestion patterns
Obviousness Reasoning
Known technique of integrating sensor technologies with pharmaceutical compositions to enhance monitoring and control
Source Patent Element
Pharmaceutical composition with abuse-deterrent properties
PTD Variation
Blockchain-based secure data storage integrated with prescription verification
Obviousness Reasoning
Logical extension of existing abuse prevention strategies using emerging digital authentication technologies
Source Patent Element
Pharmaceutically active ingredient with narrow therapeutic index
PTD Variation
Nanomaterial-based sensors detecting environmental factors to optimize drug release
Obviousness Reasoning
Predictable application of nanotechnology to enhance existing pharmaceutical monitoring and control mechanisms
Source Patent Element
Composition designed to suppress peak plasma concentration
PTD Variation
Hybrid system using machine learning to predict optimal dosage and adjust release rate
Obviousness Reasoning
Routine combination of computational predictive modeling with existing pharmaceutical formulation techniques
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857629 and the published technical disclosure, a person of ordinary skill in the art would find the claimed variations obvious and anticipated, as the proposed technological integrations represent predictable combinations of known pharmaceutical formulation strategies and emerging digital monitoring technologies, thereby rendering subsequent claims of novelty invalid under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,629
TitleMethods and compositions for self-regulated release of active pharmaceutical ingredient
Assignee(s)Acurx Pharmaceuticals, Inc.